Nektar Therapeutics (NKTR) Cash from Investing Activities (2010 - 2026)

Nektar Therapeutics' Cash from Investing Activities history runs 17 years deep, the most recent figure standing at -$350.8 million for Q1 2026.

• On a quarterly basis, Cash from Investing Activities fell 902.92% year-over-year to -$350.8 million in Q1 2026; TTM through Mar 2026 was -$395.7 million, a 336.93% decrease from a year earlier, with the FY2025 full-year figure at -$1.2 million, down 100.84% from the prior year.
• Cash from Investing Activities declined to -$350.8 million in Q1 2026 per NKTR's latest filing, from $372000.0 in the prior quarter.
• Across five years, Cash from Investing Activities topped out at $130.3 million in Q1 2022 and bottomed at -$350.8 million in Q1 2026.
• The 5-year median for Cash from Investing Activities is $40.6 million (2023), against an average of $17.4 million.
• Across the five-year window, Cash from Investing Activities surged 13521.08% in 2022 and slumped 902.92% in 2026, its largest moves.
• Year by year, Cash from Investing Activities stood at $40.0 million in 2022, then slumped by 56.56% to $17.4 million in 2023, then soared by 246.4% to $60.2 million in 2024, then plunged by 99.38% to $372000.0 in 2025, then plunged by 94398.12% to -$350.8 million in 2026.
• Per Business Quant, the three latest NKTR Cash from Investing Activities figures stand at -$350.8 million (Q1 2026), $372000.0 (Q4 2025), and -$94.9 million (Q3 2025).